Aripiprazole once-monthly for patients diagnosed with bipolar I disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed
Journal of Affective Disorders · 2026-11 · 413 · 122190
DOI: 10.1016/j.jad.2026.122190 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2026-11. Verfasst von Leslie Citrome und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA. Hauptthemen laut MEDLINE: Bipolar Disorder, Aripiprazole, Antipsychotic Agents. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Otsuka Pharmaceutical Development & Commercialization Inc, H Lundbeck A/S, Lundbeck USA.
Abstract (Originalsprache)
BACKGROUND: This post hoc analysis assessed the benefit-risk profile of aripiprazole once-monthly 400 mg (AOM 400) as a long-term maintenance treatment in patients diagnosed with bipolar I disorder (BP-I), using the evidence-based metrics of number needed to treat (NNT), number needed to harm (NNH), and the likelihood to be helped or harmed (LHH). METHODS: Data were derived from a double-blind, randomized withdrawal study that evaluated the efficacy and safety/tolerability of AOM 400 versus placebo over 52 weeks (NCT01567527). The main efficacy outcome was the proportion of patients free from recurrence of any mood episode, while the main safety/tolerability outcome was the incidence of patient discontinuation due to treatment-emergent adverse events (TEAEs). RESULTS: Overall, 73.5% of 132 patients randomized to AOM 400 and 48.9% of 133 patients randomized to placebo were free from recurrence of any mood episode at Week 52 (NNT = 5 [95% CI: 3,8]). NNT (95% CI) values were 5 (4, 9), 4 (3, 7), and-116 (not significant) for patients free from recurrence of a manic mood episode, mixed mood episode, and depressive mood episode, respectively. Discontinuation due to TEAEs was lower with AOM 400 (17.4%) versus placebo (25.6%), resulting in a negative NNH. Using an imputed NNH versus placebo of 1000, LHH was 200 for patients free from recurrence of any mood episode relative to discontinuation due to any TEAE at 52 weeks. CONCLUSIONS: Data suggest a favorable benefit-risk profile for AOM 400 versus placebo as a long-term maintenance treatment for BP-I.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA.
- Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.
- Lundbeck LLC, Deerfield, IL, USA.
- Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA. Electronic address: karimah.bell@gmail.com.
Förderung
- Otsuka Pharmaceutical Development & Commercialization Inc
- H Lundbeck A/S
- Lundbeck USA
Zitieren
APA
Citrome, L., Zhang, Z., Hutson Walker, A. M., Atkins, N., & Bell Lynum, K. S. (2026). Aripiprazole once-monthly for patients diagnosed with bipolar I disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders, 413, 122190. https://doi.org/10.1016/j.jad.2026.122190
Vancouver
Citrome L, Zhang Z, Hutson Walker AM, Atkins N, Bell Lynum KS. Aripiprazole once-monthly for patients diagnosed with bipolar I disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders. 2026;413:122190. doi:10.1016/j.jad.2026.122190
BibTeX
@article{Citrome2026,
author = {Citrome, Leslie and Zhang, Zhen and Hutson Walker, Anne M and Atkins, Norman and Bell Lynum, Karimah S},
title = {Aripiprazole once-monthly for patients diagnosed with bipolar I disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed},
journal = {Journal of Affective Disorders},
year = {2026},
volume = {413},
pages = {122190},
doi = {10.1016/j.jad.2026.122190}
}
EUVIMED